Withdrawn trial: could glofitamab stop hidden lymphoma cells?
NCT ID NCT06670105
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study aimed to see if the drug glofitamab could prevent large B-cell lymphoma from coming back in patients who had achieved complete remission but still had minimal residual disease (MRD) after standard chemotherapy. The trial was withdrawn before any patients were enrolled, so no results are available. Glofitamab is given by vein and works by helping the immune system attack cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- glofitamab
- What this could lead to
- If it works, this could help prevent lymphoma from coming back in patients who still have traces of the disease after initial treatment.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data are available. The approach is still experimental, and glofitamab may cause side effects like infusion reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Can a targeted drug boost standard chemo for an aggressive lymphoma?
- Engineered immune cells take aim at tough childhood leukemia
- Scientists build a biobank to crack the mystery of CAR-T cell failure
- Boosting CAR t cells: could a pill make lymphoma therapy more effective?
- Military study probes Toxins' role in lymphoma